TY - JOUR
T1 - Peribulbar Corticosteroids for Ocular Myasthenia Gravis
AU - Lasry, Rachel
AU - Gotkine, Marc
AU - Kruger, Joshua M.
N1 - Publisher Copyright:
© 2024 by North American Neuro-Ophthalmology Society.
PY - 2024/9/1
Y1 - 2024/9/1
N2 - Background: Ocular myasthenia gravis is treated predominantly by oral medications, with the potential for systemic adverse effects. Successful treatment has been achieved using peribulbar dexamethasone. We assessed the effect of peribulbar dexamethasone or triamcinolone (40-mg Triesence), a longer-acting corticosteroid, targeting the peribulbar area as opposed to directly injecting the affected extraocular muscle. This more convenient and secure approach holds the potential for straightforward integration within clinical environments. Methods: Retrospective chart review. Results: Five patients were identified that were treated with peribulbar corticosteroids. In 4 of the 5 cases, ophthalmoparesis was unilateral. One case had isolated ptosis, and 4 had both ptosis and ophthalmoparesis. Three of these 4 cases reported complete resolution of symptoms within weeks of a single injection. Improvement lasted between 5 to 6 months, and all patients responded to repeated injections. Conclusions: Peribulbar corticosteroids can be effective in ocular myasthenia gravis. We suggest that longer-acting agents such as triamcinolone are preferable, to reduce injection frequency.
AB - Background: Ocular myasthenia gravis is treated predominantly by oral medications, with the potential for systemic adverse effects. Successful treatment has been achieved using peribulbar dexamethasone. We assessed the effect of peribulbar dexamethasone or triamcinolone (40-mg Triesence), a longer-acting corticosteroid, targeting the peribulbar area as opposed to directly injecting the affected extraocular muscle. This more convenient and secure approach holds the potential for straightforward integration within clinical environments. Methods: Retrospective chart review. Results: Five patients were identified that were treated with peribulbar corticosteroids. In 4 of the 5 cases, ophthalmoparesis was unilateral. One case had isolated ptosis, and 4 had both ptosis and ophthalmoparesis. Three of these 4 cases reported complete resolution of symptoms within weeks of a single injection. Improvement lasted between 5 to 6 months, and all patients responded to repeated injections. Conclusions: Peribulbar corticosteroids can be effective in ocular myasthenia gravis. We suggest that longer-acting agents such as triamcinolone are preferable, to reduce injection frequency.
UR - http://www.scopus.com/inward/record.url?scp=85201790111&partnerID=8YFLogxK
U2 - 10.1097/wno.0000000000002148
DO - 10.1097/wno.0000000000002148
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38578695
AN - SCOPUS:85201790111
SN - 1070-8022
VL - 44
SP - 419
EP - 422
JO - Journal of Neuro-Ophthalmology
JF - Journal of Neuro-Ophthalmology
IS - 3
ER -